Markets & Investing
Greg Mayes, CEO of Reunion, Sits in the Investor Hotseat on January 16th
During this edition of the Investor Hotseat, host Dustin Robinson of Iter Investments is joined by Greg Mayes of Reunion Neuroscience. Greg currently leads…
During this edition of the Investor Hotseat, host Dustin Robinson of Iter Investments is joined by Greg Mayes of Reunion Neuroscience.
Greg currently leads Reunion Neuroscience ($REUN) as President and CEO and Board Member (2022 to present). As Reunion’s President and CEO, Mr. Mayes’ initial focus is on the successful completion of the Company’s Phase 1 clinical trial with its lead asset, RE104, a novel serotonergic psychedelic, which commenced in August 2022, and the planned launch of its Phase 2 study in postpartum depression, which is expected to commence in 2023. Mr. Mayes will also drive and accelerate Reunion’s preclinical RE200 research, which is focused on the discovery of selective and specific serotonergic psychedelics.
How will Greg handle the hot seat? Tune in to find out.
As always, this will be a live event. You’ll be able to stream it from the Psychedelic Invest website, YouTube, LinkedIn, Facebook, Twitch, and Twitter. If you miss it, though, don’t worry. It will be recorded and available across those channels after the event.
If you’d like to attend the live event, you can set a reminder on Youtube or LinkedIn. Or, you can return to the Hotseat livestream page at the time of the event.
To RSVP to ensure your spot, please fill out the form below.
A Transcription Will Be Available Following the Event
-
Psilocybin1 week ago
Psychedelic Underground Celebrated in San Francisco on Bicycle Day Weekend
-
Psychedelics7 days ago
Compass Pathways and Journey Clinical Establish Research Collaboration Agreement To Inform the Training of Healthcare Providers and Delivery Model for COMP360 Psilocybin Treatment, If Approved for Treatment-Resistant Depression
-
Psychedelics5 days ago
Freedom Biosciences Announces FDA Approval of IND Application for FREE001 in Patients with Treatment-Resistant Depression
-
Psychedelics7 days ago
Cybin to Participate at the 27th Annual Milken Institute Global Conference
-
Law & Regulation4 days ago
Compass Pathways, Journey Clinical to develop psilocybin treatment delivery model
-
Psychedelics6 days ago
Behold! A New Mushroom Emoji Has Arrived!
-
Ketamine5 days ago
DEA poised to move cannabis to Schedule III
-
Psychedelics6 days ago
Behold! A New Mushroom Emoji Has Arrived!